{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:25:45Z","timestamp":1789863945027,"version":"4.0.1"},"reference-count":51,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Substance Use and Addictions Program","award":["1819-HQ-000054"],"award-info":[{"award-number":["1819-HQ-000054"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,12,11]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluates the prevalence and correlates of opioid agonist therapy (OAT) discontinuation across British Columbia (BC), using a sample of individuals who used substances and accessed harm reduction sites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This study uses data from the 2019 cross-sectional Harm Reduction Client Survey (HRCS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The 2019 survey was administered from October to December at 22 harm reduction supply distribution sites across the 5 Regional Health Authorities of BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The 2019 HRCS was administered among individuals who used illicit substances in the past 6 months and were aged 19 years and above.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>\n                      The primary outcome was defined as self-reported discontinuation of OAT in the past 6 months. Measures of association (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      and Fisher\u2019s exact tests) and logistic regression models were used to assess the strength of association between OAT discontinuation and demographic, socioeconomic, accessibility, drug use and harm reduction correlates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 194 participants included, 59.8% self-identified as cis man, 37.6% self-identified as Indigenous, 38.1% were aged 30\u201339 years and 43.8% had discontinued OAT in the past 6 months. Multivariable logistic regression analyses identified that those aged \u226550 years (AOR=0.12, 95%\u2009CI (0.03 to 0.45)) and those who took the survey in medium\/large urban areas (AOR=0.27, 95%\u2009CI (0.07 to 0.98)) were significantly less likely to discontinue OAT, while those who experienced an overdose in the past 6 months were significantly more likely (AOR=3.77, 95%\u2009CI (1.57 to 9.03)) to have discontinued OAT in the past 6 months. Substance use, including opioids and stimulants, was similar among those who continued and discontinued OAT. Of the 73 participants who discontinued OAT and provided a reason, one-third reported discontinuing OAT because treatment was not effective, 27.4% could not get to the pharmacy during open hours, 23.3% could not make their clinic appointment and 15.1% reported challenges with transportation\/travel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>OAT discontinuation prevention efforts for individuals using substances in BC need to address disparities in healthcare accessibility, especially in rural areas and among younger individuals. Continued access to harm reduction services can allow for safer consumption of substances for individuals enrolled in OAT programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-090704","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T04:02:59Z","timestamp":1737000179000},"page":"e090704","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Opioid agonist therapy discontinuation in British Columbia: a cross-sectional study of people who access harm reduction services"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-1203","authenticated-orcid":false,"given":"Kimia","family":"Ziafat","sequence":"first","affiliation":[{"name":"The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Liu","sequence":"additional","affiliation":[{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Kievit","sequence":"additional","affiliation":[{"name":"The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Papamihali","sequence":"additional","affiliation":[{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Graham","sequence":"additional","affiliation":[{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5489-014X","authenticated-orcid":false,"given":"Michael","family":"Otterstatter","sequence":"additional","affiliation":[{"name":"The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2295-393X","authenticated-orcid":false,"given":"Jane A","family":"Buxton","sequence":"additional","affiliation":[{"name":"The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"2025121220101275000_15.1.e090704.1","unstructured":"BCCDC mortality context app. Available: https:\/\/bccdc.shinyapps.io\/Mortality_Context_ShinyApp\/ [Accessed 25 Feb 2022]."},{"key":"2025121220101275000_15.1.e090704.2","unstructured":"British Columbia Coroners Service . Unregulated Drug Death- BC, Available: https:\/\/www2.gov.bc.ca\/gov\/content\/life-events\/death\/coroners-service\/statistical-reports [Accessed 16 May 2024]."},{"key":"2025121220101275000_15.1.e090704.3","unstructured":"British Columbia Centre on Substance Use . Opioid use disorder. 2022. Available: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2022\/02\/Opioid-Use-Disorder-Practice-Update-February-2022.pdf [Accessed 25 Feb 2022]."},{"key":"2025121220101275000_15.1.e090704.4","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/add.15736","article-title":"Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia","volume":"117","author":"Chaillon","year":"2022","journal-title":"Addiction"},{"key":"2025121220101275000_15.1.e090704.5","unstructured":"NIDA . Medication treatment of opioid use disorder can protect against overdose death. 2021. Available: https:\/\/nida.nih.gov\/news-events\/nida-notes\/2021\/05\/medication-treatment-opioid-use-disorder-can-protect-against-overdose-death [Accessed 10 Feb 2022]."},{"key":"2025121220101275000_15.1.e090704.6","unstructured":"BCCDC . Overdose response indicators. 2022. Available: http:\/\/www.bccdc.ca\/health-professionals\/data-reports\/overdose-response-indicators [Accessed 16 May 2022]."},{"key":"2025121220101275000_15.1.e090704.7","unstructured":"Centre for Addiction and Mental Health . Opioid agonist therapy: a synthesis of canadian guidelines for treating opioid use disorder. 2021. Available: https:\/\/www.camh.ca\/-\/media\/files\/professionals\/canadian-opioid-use-disorder-guideline2021-pdf.pdf [Accessed 26 Feb 2022]."},{"key":"2025121220101275000_15.1.e090704.8","unstructured":"BC Centre for Disease Control . Unregulated drug poisoning emergency. 2019. Available: http:\/\/www.bccdc.ca\/health-professionals\/data-reports\/substance-use-harm-reduction-dashboard [Accessed 16 Mar 2024]."},{"key":"2025121220101275000_15.1.e090704.9","doi-asserted-by":"crossref","first-page":"108799","DOI":"10.1016\/j.drugalcdep.2021.108799","article-title":"Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018","volume":"225","author":"Krebs","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025121220101275000_15.1.e090704.10","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/add.14947","article-title":"The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada","volume":"115","author":"Piske","year":"2020","journal-title":"Addiction"},{"key":"2025121220101275000_15.1.e090704.11","doi-asserted-by":"crossref","first-page":"108647","DOI":"10.1016\/j.jsat.2021.108647","article-title":"Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada","volume":"133","author":"Kurz","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2025121220101275000_15.1.e090704.12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/add.15168","article-title":"Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia","volume":"116","author":"Geddes","year":"2021","journal-title":"Addiction"},{"key":"2025121220101275000_15.1.e090704.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-021-00473-9","article-title":"Retention in the Austrian opioid agonist treatment system: a national prospective cohort study","volume":"18","author":"Busch","year":"2021","journal-title":"Harm Reduct J"},{"key":"2025121220101275000_15.1.e090704.14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsat.2018.08.009","article-title":"Factors associated with methadone maintenance therapy discontinuation among people who inject drugs","volume":"94","author":"Lo","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"2025121220101275000_15.1.e090704.15","doi-asserted-by":"crossref","first-page":"108005","DOI":"10.1016\/j.drugalcdep.2020.108005","article-title":"Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting","volume":"212","author":"Dong","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"2025121220101275000_15.1.e090704.16","doi-asserted-by":"crossref","first-page":"108844","DOI":"10.1016\/j.drugalcdep.2021.108844","article-title":"The relationship between crystal methamphetamine use and methadone retention in a prospective cohort of people who use drugs","volume":"225","author":"Mackay","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025121220101275000_15.1.e090704.17","doi-asserted-by":"crossref","first-page":"103602","DOI":"10.1016\/j.drugpo.2022.103602","article-title":"Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: Findings from the 2019 Harm Reduction Client Survey","volume":"102","author":"Lukac","year":"2022","journal-title":"Int J Drug Policy"},{"key":"2025121220101275000_15.1.e090704.18","doi-asserted-by":"publisher","DOI":"10.1111\/add.14398"},{"key":"2025121220101275000_15.1.e090704.19","unstructured":"George R , Steinberg A , Buxton J . BC harm reduction client survey: background and significant findings throughout the years. Vancouver, 2021. Available: http:\/\/www.bccdc.ca\/Health-Professionals-Site\/Documents\/Harm-Reduction-Reports\/Harm%20Reduction%20Client%20Survey%20Findings_May%202021.pdf [accessed 02 Apr 2022]"},{"key":"2025121220101275000_15.1.e090704.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025121220101275000_15.1.e090704.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2025121220101275000_15.1.e090704.22","doi-asserted-by":"crossref","first-page":"103574","DOI":"10.1016\/j.drugpo.2021.103574","article-title":"Investigating opioid preference to inform safe supply services: A cross sectional study","volume":"101","author":"Ferguson","year":"2022","journal-title":"Int J Drug Policy"},{"key":"2025121220101275000_15.1.e090704.23","doi-asserted-by":"crossref","first-page":"102665","DOI":"10.1016\/j.drugpo.2020.102665","article-title":"Known fentanyl use among clients of harm reduction sites in British Columbia, Canada","volume":"77","author":"Karamouzian","year":"2020","journal-title":"Int J Drug Policy"},{"key":"2025121220101275000_15.1.e090704.24","unstructured":"2019 harm reduction client survey how did you use it? did you have a prescription for it? methadone (methadose\/metadol)."},{"key":"2025121220101275000_15.1.e090704.25","doi-asserted-by":"crossref","unstructured":"Akaike H . Akaike\u2019s information criterion. Available: https:\/\/doi.org\/10.1007\/978-3-642-04898-2_110 [Accessed 09 May 2022].","DOI":"10.1007\/978-3-642-04898-2_110"},{"key":"2025121220101275000_15.1.e090704.26","unstructured":"McFadden D . Conditional logit analysis of qualitative choice behavior. In: Frontiers in Econometrics. 1973: 105\u201342."},{"key":"2025121220101275000_15.1.e090704.27","doi-asserted-by":"crossref","unstructured":"Hosmer DW , Lemeshow S , Sturdivant RX . Model\u2010Building strategies and methods for logistic regression. In: Wiley Series in Probability and Statistics - Wiley Online Library, Applied Logistic Regression. 2013: 89\u2013151. Available: https:\/\/doi.org\/10.1002\/9781118548387.ch4","DOI":"10.1002\/9781118548387.ch4"},{"key":"2025121220101275000_15.1.e090704.28","unstructured":"CAMH . Mental illness and addiction: facts and statistics. 2022. Available: https:\/\/www.camh.ca\/en\/driving-change\/the-crisis-is-real\/mental-health-statistics"},{"key":"2025121220101275000_15.1.e090704.29","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S39776"},{"key":"2025121220101275000_15.1.e090704.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2010.08.017"},{"key":"2025121220101275000_15.1.e090704.31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1300\/J020v21n01_02","article-title":"Young adults in alcohol-other drug treatment: An understudied population","volume":"21","author":"Mason","year":"2003","journal-title":"Alcohol Treat Q"},{"key":"2025121220101275000_15.1.e090704.32","doi-asserted-by":"crossref","first-page":"107005","DOI":"10.1016\/j.addbeh.2021.107005","article-title":"Investigating interventions that lead to the highest treatment retention for emerging adults with substance use disorder: A systematic review","volume":"122","author":"Dalton","year":"2021","journal-title":"Addict Behav"},{"key":"2025121220101275000_15.1.e090704.33","unstructured":"Rush B , Rotondi NK . Wait times for publicly funded addiction and problem gambling treatment agencies in Ontario, Canada, 2013. Available: http:\/\/www.connexontario.ca\/"},{"key":"2025121220101275000_15.1.e090704.34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jrh.12129","article-title":"Barriers and Facilitators to Substance Use Treatment in the Rural South: A Qualitative Study","volume":"32","author":"Browne","year":"2016","journal-title":"J Rural Health"},{"key":"2025121220101275000_15.1.e090704.35","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3109\/10826084.2014.891615","article-title":"Barriers to substance abuse treatment in rural and urban communities: counselor perspectives","volume":"49","author":"Pullen","year":"2014","journal-title":"Subst Use Misuse"},{"key":"2025121220101275000_15.1.e090704.36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.17269\/s41997-021-00504-9","article-title":"The need to prioritize research, policy, and practice to address the overdose epidemic in smaller settings in Canada","volume":"112","author":"Bardwell","year":"2021","journal-title":"Can J Public Health"},{"key":"2025121220101275000_15.1.e090704.37","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-018-0273-3","article-title":"Mobile supervised consumption services in Rural British Columbia: lessons learned","volume":"16","author":"Mema","year":"2019","journal-title":"Harm Reduct J"},{"key":"2025121220101275000_15.1.e090704.38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jrh.12264","article-title":"Perceived Barriers and Facilitators to Providing Methadone Maintenance Treatment Among Rural Community Pharmacists in Southwestern Ontario","volume":"34","author":"Fonseca","year":"2018","journal-title":"J Rural Health"},{"key":"2025121220101275000_15.1.e090704.39","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/emp2.12289","article-title":"Microdosing and standard-dosing take-home buprenorphine from the emergency department: A feasibility study","volume":"1","author":"Moe","year":"2020","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"2025121220101275000_15.1.e090704.40","doi-asserted-by":"crossref","DOI":"10.1002\/emp2.12409","article-title":"Emergency physician perspectives on initiating buprenorphine\/naloxone in the emergency department: A qualitative study","volume":"2","author":"Dong","year":"2021","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"2025121220101275000_15.1.e090704.41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.1271"},{"key":"2025121220101275000_15.1.e090704.42","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-021-00521-4","article-title":"Factors associated with opioid overdose during medication-assisted treatment: How can we identify individuals at risk?","volume":"18","author":"Au","year":"2021","journal-title":"Harm Reduct J"},{"key":"2025121220101275000_15.1.e090704.43","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/dar.13690","article-title":"Longitudinal latent polysubstance use patterns among a cohort of people who use opioids in Vancouver, Canada","volume":"42","author":"Karamouzian","year":"2023","journal-title":"Drug Alcohol Rev"},{"key":"2025121220101275000_15.1.e090704.44","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060447","article-title":"Motivations for concurrent use of uppers and downers among people who access harm reduction services in British Columbia, Canada: findings from the 2019 Harm Reduction Client Survey","volume":"12","author":"Steinberg","year":"2022","journal-title":"BMJ Open"},{"key":"2025121220101275000_15.1.e090704.45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.drugalcdep.2019.03.014","article-title":"Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths","volume":"200","author":"Barocas","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2025121220101275000_15.1.e090704.46","doi-asserted-by":"crossref","first-page":"108722","DOI":"10.1016\/j.drugalcdep.2021.108722","article-title":"Community overdose surveillance: Comparing substances collected from the death scene investigation to toxicology results","volume":"224","author":"Lockwood","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025121220101275000_15.1.e090704.47","doi-asserted-by":"crossref","unstructured":"O\u2019donnell J , Mattson CL , Hunter CT , et al . Vital signs: characteristics of drug overdose deaths involving opioids and stimulants-24 states and the district of columbia, january-june 2019. 2019. Available: https:\/\/www.cdc.gov\/drugoverdose\/od2a\/index.html","DOI":"10.15585\/mmwr.mm6935a1"},{"key":"2025121220101275000_15.1.e090704.48","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/10826084.2016.1271432","article-title":"Heroin and Methamphetamine Injection: An Emerging Drug Use Pattern","volume":"52","author":"Al-Tayyib","year":"2017","journal-title":"Subst Use Misuse"},{"key":"2025121220101275000_15.1.e090704.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.07.009"},{"key":"2025121220101275000_15.1.e090704.50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/CXA.0000000000000015","article-title":"Large Variation in Provincial Guidelines for Urine Drug Screening during Opioid Agonist Treatment in Canada","volume":"9","author":"Moss","year":"2018","journal-title":"Can J Addict"},{"key":"2025121220101275000_15.1.e090704.51","unstructured":"Statistics Canada . Population centre and rural area classification 2016. 2017. Available: https:\/\/www.statcan.gc.ca\/en\/subjects\/standard\/pcrac\/2016\/introduction [Accessed 04 Jun 2023]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-090704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:10:27Z","timestamp":1765599027000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-090704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,15]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjopen-2024-090704"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-090704","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}